29
Participants
Start Date
August 4, 2022
Primary Completion Date
October 31, 2026
Study Completion Date
October 31, 2027
Busulfan (Busulfex)
For myeloablative conditioning: Busulfan (Bu，3.2 mg/kg/d IV -8d \~-6d) For reduced intensity conditioning: (Bu，3.2 mg/kg/d IV -7d\~-5d)
Cyclophosphamide (CTX)
Cyclophosphamide is only used in myeloablative conditioning (Cy，1.8g/m2, -5d, -4d)
Fludarabine (Fludara)
For myeloablative conditioning: Fludarabine (Flu，30 mg/m2/d IV -6d \~ -2d) For reduced intensity conditioning: Fludarabine（Flu，30mg/m2 /d IV -10d\~-5d）
Semustine (MeCCNU)
For both myeloablative and reduced intensity conditioning: Semustine (MECCNU，250 mg/m2 orally-3d).
RECRUITING
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
He Huang
OTHER